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Abstract
Objective: Pyridoxine, is essential in the metabolism of many classes of food, we aimed at determining 
the effect of its supplementation on the quality of life (QoL) of patients with chronic lymphocytic 
leukaemia (CLL). 
Methods: This study compared the (QoL) and haematological parameters of CLL patients before and 
after the administration of pyridoxine. Data obtained were analyzed using SPSS version 19. 
Results: There was improvement in the QoL of the patients after pyridoxine supplementation; Majority of 
the parameters that make up the physical functional scales was significantly higher after pyridoxine 
supplementation. There were also significant improvements in insomnia, appetite loss and constipation 
after pyridoxine supplementation. 
Conclusion: Pyridoxine supplementation in patients with CLL marginally improved quality of life.
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Effet de la supplémentation en pyridoxine sur la qualité de vie des 
patients atteints de leucémie lymphoïde chronique
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Abstrait
Objectif: La pyridoxine, essentielle au métabolisme de nombreuses classes d’aliments, nous avons 
cherché à déterminer l’effet de sa supplémentation sur la qualité de vie des patients atteints de leucémie 
lymphoïde chronique (LLC).
Méthodes: Cette étude a comparé les paramètres (qualité de vie) et hématologiques des patients atteints 
de LLC avant et après l'administration de pyridoxine. Les données obtenues ont été analysées avec SPSS 
version 19.
Résultats: La qualité de vie des patients s'est améliorée après la supplémentation en pyridoxine; La 
majorité des paramètres constituant les échelles physiques et fonctionnelles était significativement plus 
élevée après la supplémentation en pyridoxine. Il y avait aussi des améliorations significatives dans 
l'insomnie, la perte d'appétit et la constipation après une supplémentation en pyridoxine.
Conclusion: La supplémentation en pyridoxine chez les patients atteints de LLC a légèrement amélioré la 
qualité de vie.
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INTRODUCTION
Pyridoxine is a vitamin that is essential in 
the metabolism of protein, carbohydrates, fatty 
acids, and several other substances, including 
brain amines (1), where as chronic lymphocytic 
leukaemia (CLL) is a blood cancer that affects 
mainly the elderly. Pyridoxine's benefit in 
patients with tuberculosis has been established as 
it is known to prevent the development of 
peripheral neuropathy during isoniazid therapy. 
Chronic lymphocytic leukaemia is the 
commonest form of leukaemia in adults in 
Nigeria (2). Low emotional wellbeing score for 
CLL patients has been reported compared to the 
general population and with patients with other 
forms of cancers (3). The use of chemotherapy 
alone in the treatment of CLL has not improved 
on these parameters significantly (4), therefore 
there is the need to search for agents that could 
improve the QoL of this group of patients. 
Pyridoxine is a compound that has 
vitamin B6 activities. Large proportions of the 
naturally occurring pyridoxine are not 
bioavailable as they occur in glycosylated poorly 
absorbable form. It performs a wide range of 
activities especially as a co-enzyme assisting in 
many metabolic activities amongst which are 
metabolism of carbohydrate and lipid. 
Pyridoxine acts by converting tryptophan to 
niacin or serotonin, breaking down of glycogen to 
glucose-1-phosphate, conversion of oxalate to 
glycine, synthesis of gamma aminobutyric acid 
(GABA) within the CNS, and synthesis of heme 
necessary for the production of red blood cells.
As stated earlier, pyridoxine has been 
found to be very useful in preventing 
polyneuropathy in tuberculosis patients that are 
on isoniazid (1). It is also useful in reducing pains 
and may therefore be useful in improving the QoL 
of patients with CLL in whom pain is one of the 
major contributors to poor quality of life (5). It 
has been revealed that there is a 60% increase in 
daily requirement of pyridoxine in physiologic 
states with increased metabolic activities like 
pregnancy, lactation and exercise (6). Since one 
of the cardinal features of CLL is increased 
metabolism (hypermetabolic state), pyridoxine 
may be of great value in this condition. 
Investigations of the benefit of vitamins in 
various medical conditions have been going on. 
An example was a study in children with malaria 
which showed improved haematological indices 
on those that had vitamin A supplementation 
during treatment (7). Rich sources of pyridoxine 
include beef liver, fish, and starchy vegetable, 
and because of prevalent poor economy, most of 
the patients may not be able to afford these food 
items and may therefore be deficient of this vital 
vitamin.
We therefore aim to determine the 
beneficial effect or otherwise of pyridoxine 
supplementation (an important coenzyme) in 
CLL patients, an agent which is of immense 
benefit to patients with tuberculosis.
MATERIALS AND METHODS 
This was a longitudinal study that sought 
to determine the impact of pyridoxine 
supplementation on the quality of life and on the 
haematological parameters of CLL patients in 
Makurdi north-central, Nigeria. Ethical clearance 
f o r  t h i s  s t u d y  r e f e r e n c e d  
BSUTH/MKD/HREC/2013B/2018/0019 
(Appendix A) was obtained from the Health 
Research and Ethics Committee of the Benue 
State University Teaching Hospital, Makurdi. 
The study population comprised chronic 
lymphocytic leukaemia patients that attended the 
outpatient clinic of the Benue State University 
Teaching Hospital, (BSUTH) Makurdi and the 
Federal Medical Centre, (FMC) Makurdi within 
the period of the study (January-August 2018). 
The sample size was calculated using the 
formula developed by Xavier et al (8) for 
longitudinal studies. The calculated minimum 
sample size was 50. An additional 50 patients 
were recruited to make up for those that would be 
lost to follow up. Participants were recruited from 
the Haematology out-patient clinic of the 
BSUTH, Makurdi and FMC, Makurdi. They 
were recruited consecutively as they presented 
for routine consultations, until a total of 100 
participants was reached. 
Exclusion criteria included: Objection to 
participate in the study, patients less than 18 years 
of age and patients with diagnosis other than 
CLL. Immediately after the details of the study 
were explained to the participants and their 
consent obtained, the EORTC (version 3) quality 
of life questionnaires (QLQ-C30) were issued to 
them, and baseline samples for complete blood 
count were collected. The questionnaires were 
administered by the research assistant, who also 
guided the participants in filling them.
The EORTC (version 3) Quality of life 
questionnaire (QLQ-C30) is a 30-item Likert-
type validated questionnaire, which has the 
advantage of self-administration to respondents. 
This questionnaire was field-tested in a cross-
cultural sample of cancer patients in 13 countries 
to confirm the hypothesized scale structure, to 
establish reliability and to evaluate validity (8). It 
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demonstrated internal consistency for the group 
under study with a calculated Cronbach alpha of 
0.73 in a pilot study. A high score for a functional 
scale represents a high / healthy level of 
functioning, a high score for the global health 
status / QoL represents a high QoL, but a high 
score for a symptom scale / item represents a high 
level of symptomatology / problems. 
On completion of the questionnaire, 2ml 
of venous blood was withdrawn from the cubital 
vein using a 5ml syringe and observing aseptic 
procedures. The blood was dispensed into an 
EDTA bottle for analysis of haematological 
parameters. These parameters included red blood 
cell count, haematocrit (HCT), mean corpuscular 
volume (MCV), mean corpuscular haemoglobin 
(MCH), mean corpuscular haemoglobin 
concentration (MCHC), white blood cell count, 
differential leukocyte count, and platelet count 
using the Sysmex haematology auto-analyzer 
(Sysmex Corporation of America) at the 
Haematology laboratory of BSUTH, Makurdi. 
These tests were done within 24 hours after 
collection. The performance of the auto-analyzer 
was validated using quality control samples 
which were run with each batch of the sample 
specimen and by manual counts. Participants 
were there after given supplemental tablets of 
pyridoxine at a dose of 25mg daily to be taken in 
addition to their chemotherapy for a period of 
four months. The participants were mainly on a 
combination of chlorambucil and prednisolone 
for varying number of cycles depending on their 
responses. The pyridoxine was sourced from 
pharmaceutical outlets where the researchers had 
no conflict of interests. At the end of this period, 
the questionnaires were re-administered and their 
full blood count taken again for comparison.
Data obtained from these analyses were 
analyzed by the statistical package for social 
sciences version 19. The differences in quality of 
life and haematological indices were tested for 
significance using the student t-test.
RESULTS
A total of 100 (one hundred) chronic 
lymphocytic leukaemia patients were recruited, 
but 74 (seventy-four) completed the study. Fifty-
one were males while 23 were females, 
translating to a male to female ratio of 2.2: 1. The 
mean age of the participants was 62 ± 8.5 years. 
Majority (66.2%) of the participants had late 
stages (stages III and IV) of the disease. Table 1
The quality of life (QoL) of the 
participants prior to pyridoxine administration 
was significantly lower than the published data in 
the EORTIC QLQ-C30 reference value manual 
(10). All the parameters in the functional scale 
were significantly lower in our study compared to 
the reference values. In the symptom scales, our 
participants were worse off with fatigue, pain and 
financial difficulty but fared better with nausea, 
vomiting, dyspnoea, insomnia appetite loss, 
constipation and diarrhea. Table 2.
There was improvement in the global 
health status of the patients after pyridoxine 
supplementation; however, this was not 
statistically significant, but majority of the 
parameters that make up the physical functional 
scales (Physical functioning, role functioning, 
emotional functioning and cognitive functioning) 
was significantly higher after pyridoxine 
supplementation. Result also showed statistically 
significant improvements in symptoms after 
pyridoxine supplementation except for fatigue, 
Nausea, vomiting and financial difficulties. Table 
3. The total white cell count, lymphocyte count 
and granulocyte count were significantly lower 
after pyridoxine supplementation and 
chemotherapy while the haemoglobin 
concentration and the platelet count were 
significantly higher after supplementation. Table 
4.
DISCUSSION
The quality of life (QoL) of the 
participants in our study prior to pyridoxine 
administration was significantly lower than 
published data in the EORTIC QLQ-C30 
reference value manual (10). The low QoL in our 
participants may be related to late presentation of 
our patients which is demonstrated by the high 
number (66.2%) that had the late stages (Ria III 
and IV) of the disease compared to those used for 
calculating the reference values mainly stages I 
and II. It may also be as a result of fewer numbers 
of participants in our study (74) as compared to 
23,555 used for the calculating the reference 
range or it could be the effect of geographical and 
racial influences on the quality of life of this 
category of patients. The above adduced 
concerns will require further studies. The low 
QoL from our study was however in keeping with 
 the report of other studies (4,10,11,12,13) around 
the globe which demonstrated that the different 
dimensions of QoL were deteriorated by 
haematological malignancies and, probably, by 
the side effects of their treatments. Our result 
revealed that all the parameters in the functional 
scales of the QoL questionnaire were 
significantly lower compared to the reference 
values. This implied that the functional aspect of 
quality of life of our patients was worse affected 
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than the symptom aspect. In the symptom scales, 
our participants had higher scores for fatigue, 
pain, and financial difficulties but there were not 
statistically significant. This implied that our 
participants had worse symptoms (fatigue, pain 
and financial difficulties) compared to the 
reference range and this is in keeping with the fact 
that our participants presented with the late stages 
of the disease. We however recorded significantly 
milder symptoms in the rest of the parameters 
(dyspnoea, insomnia, appetite loss, constipation, 
and diarrhoea). 
There was marginal improvement in the 
global health status of our patients after 
pyridoxine supplementation; but this was not 
statistically significant. However, parameters in 
the functional scales revealed that physical 
functioning, role functioning, emotional 
functioning and cognitive functioning were 
s ignif icant ly  higher  af ter  pyr idoxine 
supplementation. Researchers had earlier 
reported a decline in QoL especially when 
patients were undergoing chemotherapy (14,15). 
The improved QoL of our patients after 
pyridoxine supplementation may be an indication 
that pyridoxine is beneficial in this group of 
patients.  This finding is however contrary to 
 
what Jannique et al (16) discovered while 
working on the effect  of vitamin B 
supplementation on quality of life in community-
dwelling adults with mild cognitive impairment. 
Although pyridoxine deficiency has been noted 
to lead to increased circulating homocysteine, 
which is a risk factor for neuropsychiatric 
disorders including seizures, migraine, chronic 
 pain and depression, Malouf et al (17) in a 
systematic review revealed no evidence for short-
term benefit from pyridoxine in improving mood 
(depression, fatigue and tension symptoms) or 
cognitive functions.
Our result also showed statistically 
significant improvements in insomnia and 
appetite loss after pyridoxine supplementation. 
Although vitamins have not been reported to have 
soporific effects, B vitamins have been advanced 
as preventive for insomnia based on research that 
suggests deficiencies in vitamin B6 promote 
psychological distress and ensuing sleep 
 
disturbance (18) and report by Morin et al (19) 
earlier indicated that vitamin intakes improve 
sleep. Another study has identified vitamin B 
complex as a helpful treatment of nocturnal leg 
cramps (20) and this may improve the sleep 
quality of the individual. The precise mechanism 
for this observation was not however clear. The 
significant improvement in appetite following 
pyridoxine supplementation in our study is in 
keeping with what researchers demonstrated in 
Rex Rabbit where it was discovered that 
pyridoxine increased food intake significantly 
and in a dose-dependent manner (21).
Other symptoms (fatigue, nausea and 
vomiting, and pain) also improved but not 
significantly after pyridoxine supplementation. 
Report of mood changes resulting from 
pyridoxine deficiency and leading to depression, 
anxiety, irritability and pain is well documented 
(22-24). These effects were attributed to the fact 
that pyridoxine is involved in the production of 
several neurotransmitters especially gama-
aminobutyric acid (GABA) and serotonin which 
help control anxiety, depression and pains. 
Improvement in fatigue post pyridoxine may be 
linked to the fact that pyridoxine plays a vital role 
in haemoglobin-the protein that carries oxygen 
round the body-synthesis. Besides feeling tired 
from anemia, pyridoxine deficiency could also 
potentially contribute to tiredness due to its role 
in making the sleep-promoting hormone 
melatonin (25-26). 
The total white cell count, lymphocyte 
count and granulocyte count were significantly 
lower after pyridoxine supplementation while the 
haemoglobin concentration and the platelet count 
were significantly higher after supplementation. 
The haematological changes cannot be 
immediately differentiated from the actions of 
chemotherapeutic agents. A study involving 
those patients that are off chemotherapy will help 
in differentiating the two. But the improvements 
in haemoglobin concentration and platelet count 
may be attributed to the pyridoxine since it has 
been established as a necessary factor in the 
synthesis of heme. 
CONCLUSION
Pyridoxine supplementation in patients 
with CLL improved the physical functioning, 
some symptoms, haemoglobin concentration, 
platelet count and overall quality of life.
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Table 1: Socio-demographic characteristics of the participants 
 
Socio-demographic variables n (%) 
Age (years) 
50-59 35 (47.3) 
60-69 24 (32.4) 
70-79 15 (20.3) 
Mean ± SD 62 ± 8.5 
Sex 
Male 51 (68.9) 
Female 23 (31.1) 
Educational level 
None  8 (10.8) 
Primary 11 (14.9) 
Secondary  0   (0.0) 
Tertiary 55 (74.3) 
Occupation 
Unemployed 41 (55.4) 
Civil/Public servant 14 (18.9) 
Self-employed 19 (25.7) 
Ria stage 
I and II 25 (33.8) 
III and IV 49 (66.2) 
 
 
Table 2: Comparing quality of life of the participants prior to pyridoxine administration  
with the EORTIC QLQ-C30 reference values 
 








Global health status/QoL 61.3 ± 24.2 50.2 ± 20.3 0.0001 
Functional scales    
Physical functioning 76.7 ± 23.2 65.3 ± 15.4 0.0001 
Role functioning 70.5 ± 32.8 59.0 ± 10.2 0.0001 
Emotional functioning 71.4 ± 24.2 60.1 ± 12.1 0.0001 
Cognitive functioning 82.6 ± 21.9 56.5 ± 12.6 0.0001 
Social functioning 75.0 ± 29.1 53.3 ± 11.4 0.0001 
Symptom scales    
Fatigue 34.6 ±27.8 39.0 ± 16.8 0.1736 
Nausea and vomiting 9.1 ± 19.0 8.2 ± 14.4 0.6839 
Pain  27.0 ± 29.9 34 ± 17.5 0.0541 
Dyspnoea 21.0 ± 28.4 4.6 ± 10.5 0.0001 
Insonmia 28.9 ± 31.9 10.4 ± 5.7 0.0001 
Appetite loss 21.1 ± 31.3 9.3 ± 6.9 0.0013 
Constipation 17.5 ± 28.4 9.5 ± 4.3 0.0154 
Diarrhoea 9.0 ± 20.3 1.1 ± 0.7 0.0008 
Financial difficulties 16.3 ± 28.1 21.9 ± 14.3 0.0866 
 
QoL= quality of life 
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Table 3: Quality of life of the participants before and after pyridoxine supplementation 
 











Global health status/QoL 50.2 ± 20.3 52.1 ± 19.3 0.5604 
Functional scales    
Physical functioning 65.3 ± 15.4 75.0 ± 21.2 0.0018 
Role functioning 59.0 ± 10.2 66.7 ± 12.6 0.0001 
Emotional functioning 60.1 ± 12.1 68.0 ± 14.2 0.0004 
Cognitive functioning 56.5 ± 12.6 66.7 ± 13.4 0.0001 
Social functioning 53.3 ± 11.4 52.1 ± 18.2 0.6315 
Symptom scales    
Fatigue 39 ± 16.8 36 ± 15.7 0.2636 
Nausea and vomiting 8.2 ± 14.4 6.3 ± 12.4 0.3911 
Pain  34 ± 17.5 31 ± 20.3 0.3372 
Dyspnoea 4.6 ± 10.5 4.7 ± 12.0 0.9570 
Insonmia 10.4 ± 5.7 7.3 ± 4.1 0.0002 
Appetite loss 9.3 ± 6.9 6.2 ± 2.4 0.0004 
Constipation 9.5 ± 4.3 7.3 ± 6.5 0.0164 
Diarrhoea 1.1 ± 0.7 1.2 ± 0.4 0.2877 
Financial difficulties 21.9 ± 14.3 23 ± 12.2 0.6154 
 
 
Table 4: Haematological parameters of participants before and  
after pyridoxine supplementation and chemotherapy 
 
Parameter  Before 
pyridoxine 
supplementation 
(mean ± SD) 
After pyridoxine 
supplementation 
(mean ± SD) 
p-value 
TWBC (x109/L)  46.0 ± 43.6  23.5 ± 15.6 0.0001 
Lym (x109/L)  33.0 ± 37.3  18.2 ± 9.4 0.0013 
Gr (x109/L)   6.9 ± 4.7    5.4 ± 2.1 0.0139 
Hb (g/dL)   9.0 ± 1.8  10.1 ± 0.9 0.0001 
MCV (fL)  95.0 ± 12.7  96.0 ± 13.4 0.6442 
MCH (pg)  28.5 ± 1.9  28.7 ± 1.2  0.4480 
MCHC (g/dL)  30.1 ± 2.4  29.4 ± 1.7 0.0330 
Platelet (x109/L) 143.4 ± 63.8 172.1 ± 54.5 0.0040 
PDW (fL)     9.0 ± 2.3     8.7 ± 1.9 0.3917 
MPV (fL)     9.9 ± 1.2     8.7 ± 0.8 0.0001 
 
Key: TWBC-Total white blood cell count, Lym- lymphocyte count,   
Gr- Granulocyte count, Hb-Haemoglobin concentration, MCV-Mean cell volume,  
MCH-Mean cell volume, MCHC-Mean corpuscular haemoglobin concentration,  
PDW-Platelet distribution width, MPV-Mean platelet volume, 
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